Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
about
5-alpha-reductase inhibitors for prostate cancer preventionMolecular cancer prevention: Current status and future directionsAndrogens and prostate diseaseAdverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic ReviewEvidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasiaJNCI and cancer preventionPreventive and therapeutic efficacy of finasteride and dutasteride in TRAMP miceEffect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinicMethyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefitVariability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis5α-Reductase inhibitors and risk of high-grade or lethal prostate cancerLong-term survival of participants in the prostate cancer prevention trial.Therapy-associated effects in the prostate gland.Molecular genetics of prostate cancer: new prospects for old challengesA nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).The influence of hepatic function on prostate cancer outcomes after radical prostatectomy.Chemoprevention of prostate cancer.Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineTransition of a clinical trial into translational research: the prostate cancer prevention trial experience.Decision analysis of dutasteride use for patients with negative prostate biopsyPrevention of prostate cancer: outcomes of clinical trials and future opportunities.Lower urinary tract symptoms in men.Prostate changes related to therapy: with special reference to hormone therapy.Prostate cancers detected during 5α-reductase inhibitor use are smaller, de-differentiated, but confined when compared to controls.Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsOptimization of thiazole analogues of resveratrol for induction of NAD(P)H:quinone reductase 1 (QR1)Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?Cancer chemoprevention: a rapidly evolving field.Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerClinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyAmerican Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.Does the level of prostate cancer risk affect cancer prevention with finasteride?Finasteride in the treatment of patients with benign prostatic hyperplasia: a reviewProstate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.
P2860
Q22252970-B5AD384E-BF22-40D8-88E0-68B069556904Q26797207-99391394-CE6E-4AED-951F-F6D894754795Q27010093-30A6023D-4526-4D7B-82DC-97F4F1A4C2CEQ28069186-5030D5BE-1582-4CF9-A985-77F8CF9B7DA8Q28077954-EDDE9C86-01E0-48A9-9D39-7C0195CE7F20Q28389384-E13AD7E2-C384-4598-B741-12F5BE740FC4Q28534518-900F5AB1-31A7-4B92-942D-626E33B462A7Q29619860-D2A9F0DF-A3DE-4657-B6CB-D6BEB1304346Q30498812-DC26E5CF-B77B-48FA-8273-6535045A13EDQ33657004-57B47744-18F1-4DFA-BDAA-1F4915942F8CQ33658285-040E6BA7-A111-4496-AF2C-13FB3CA65202Q33710942-FAF6989B-BF62-4373-B3BA-EE3BC95422A8Q33750580-2529C583-757F-458C-B153-D0B682328780Q33882778-2E029EE6-4778-4444-B50C-696502592635Q33894354-9AA00964-8E54-447D-BED2-2D364A2BE439Q34005866-39D3F99B-139F-4D12-AA2E-8D91BCBD2DFCQ34077860-0E9594E5-7E68-44D2-9F51-68ACADFDD231Q34115527-9BF560B4-B431-4A15-A006-0ECA8EC0B9E2Q34127462-C09E4906-7B10-4235-BB6E-037F2751C12CQ34142018-734CDF49-004A-43D9-8981-BB389EEF8476Q34162770-E54AE9D4-0C88-4F13-9A2A-0D8B3D2086A1Q34186757-B8737BB4-31E3-44B1-BBB7-390F2A915537Q34604979-F1FFA1E2-A15F-4767-B5A4-A7E1C9257B33Q34682926-A49FB57E-08D6-446A-A9C6-36AA6D6D8D7EQ35020507-EDDF5D90-7BD3-4670-BA9E-E43F770550AAQ35067699-F33CD93D-9B08-4228-BE41-A5B184646188Q35225398-1CFD4DEC-86C9-469E-81A4-B80FB03FFB67Q35344149-7A188271-8933-4FFB-8DCB-CF0091833E27Q35815992-3DEE4889-A4F6-4E57-882E-D491632215FCQ36413132-FAA26181-D441-46CD-9A95-25E44A141DB1Q36427947-877D330D-CE90-4894-9B2B-1D0F347C819EQ36589091-C0DDC5A6-A6FF-419B-85D0-33D48A9FD917Q36883768-5619CF17-5BA9-43AF-9BA2-0CCEAB536294Q37003415-03C79817-C6CE-40C3-B6E6-0103B615CB2AQ37009071-A6FBC514-F212-4E5F-8273-237DAD5B0012Q37103057-ADF0878A-D91E-4A50-A838-540FD66D553FQ37157589-0A0F23DC-06FB-4EE1-90EC-F47F3F98FDF2Q37217579-494974A1-F51C-4643-9A5E-9183D5FD651EQ37261063-24A36ABD-28F9-4C55-8535-D5D48CD1558EQ37330766-3029624D-C1DE-4F7D-99B7-C8453D260FAB
P2860
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
@en
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
@nl
type
label
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
@en
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
@nl
prefLabel
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
@en
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
@nl
P2093
P2860
P356
P1476
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
@en
P2093
Catherine M Tangen
Charles A Coltman
E David Crawford
Francisco Civantos
Francisco G La Rosa
Howard L Parnes
Ian M Thompson
Jonathan I Epstein
Leslie G Ford
M Scott Lucia
P2860
P304
P356
10.1093/JNCI/DJM117
P407
P50
P577
2007-09-11T00:00:00Z